Asset Details
Do you wish to reserve the book?
抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用
Do you wish to request the book?
抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用
2010
Overview
采用以铂类药物为基础联合细胞毒性药物作为非小细胞肺癌（non-small-cell lung cancer,NSCLC）的标准化一线治疗的疗效已达到相应的平台。作用于特定通路的新型分子靶向药物逐渐成为治疗NSCLC的有效药物; 某些药物的III期试验已取得阳性结果。值得注意的是,有研究证实,采用抗血管内皮生长因子（vascular endothelial growth factor,VEGF）抗体贝伐珠单抗抑制VEGF通路,以及采用表皮生长因子受体（epidermal growth factor receptor,EGFR）的小分子酪氨酸激酶抑制剂厄洛替尼或单克隆抗体（西妥昔单抗）靶向作用于EGFR通路作为一线或二线治疗方案,均可延长晚期肺癌患者的生存期。可导致肿瘤细胞存活和增殖的信号处理过程不同,为靶向作用于多种信号通路为有效的抗癌治疗策略提供了依据。因此,分子靶向药物的合理联用可能达到更好的临床疗效,并可成为对标准化疗耐药或不能耐受标准化疗的患者的可替代的治疗选择。目前的挑战在于明确应探寻哪些分子实体,以及它们的最佳联合方案。本综述旨在探讨贝伐珠单抗联合厄洛替尼抑制血管生成和EGFR信号作为治疗NSCLC的有效的非化疗方案的潜在临床疗效。其它可阻滞EGFR和血管生成通路以及互补信号通路的新型药物的联合具有独特的作用机制和较轻的毒副作用,有可能为晚期NSCLC患者的个体化治疗选择提供更多的治疗方案。
We currently cannot retrieve any items related to this title. Kindly check back at a later time.